Califf On Capitol Hill: Rally Friends, Repair Relationships
This article was originally published in The Tan Sheet
Executive Summary
The new FDA commissioner cautions rare disease advocates about fighting for ineffective treatments and looks to repair communication problems with Senate.
You may also be interested in...
Sarepta's Eteplirsen Is Centerpiece Of Senate Hearing On Expanded Access
Witnesses call for political pressure on FDA to approve the Duchenne drug; patients and advocates also urge general approval reciprocity with Europe and incentives for pediatric trials; agency was not invited to testify.
President Urges Breaking Down Drug, Device Distinctions, Regulatory Barriers
At White House summit on precision medicine, President Obama emphasized the need to break down outmoded regulations, and suggested barriers between drug and device oversight need to be loosened; FDA and NIH announced a number of new competitions and projects.
FDA Sets New Goal For Biosimilar, Drug Promotion Guidances
Agency plans to issue 102 new and revised draft guidances this year, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and ANDA refuse-to-receive standards.